Relmada Therapeutics, Inc. - Common Stock (RLMD)

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

Let's have a look at the stocks with an unusual volume in today's session.

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's have a look at the stocks with an unusual volume in today's session.

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

These stocks have an unusual volume in today's session

Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.